Silbersher v. Allergan plc

District Court, N.D. California·Decided May 7, 2024·No. 3:18-cv-03018·Unknown

Opinion

ZACHARY SILBERSHER, et al., Case No. 18-cv-03018-JCS Plaintiffs, v. ORDER DENYING MOTION FOR INDICATIVE RULING FOR POST ALLERGAN INC., et al., JUDGMENT RELIEF PURSUANT TO FRCP 60 AND 62.1 Defendants. Re: Dkt. No. 201

Following entry of judgment against him, Relator Zachary Silbersher (“Relator”) filed an appeal with the Ninth Circuit and that appeal is currently pending. Where an appeal has been docketed and remains pending, a district court cannot grant relief from a final judgment under Rule 60(b) of the Federal Rules of Civil Procedure without a remand. See Rule 62.1 advisory committee’s note; see also Balan v. Tesla Motors, Inc., 2020 WL 1248670, at *1 (W.D. Wash. Mar. 16, 2020) (citing Williams v. Woodford, 384 F.3d 567, 586 (9th Cir. 2002)). However, under Rule 62.1 of the Federal Rules of Civil Procedure, a district court may indicate to the court of appeals that it would alter its ruling if the case were remanded for that purpose. Relator brings a Motion for Indicative Ruling for Post Judgment Relief Pursuant to FRCP 60 AND 62.1 (“Motion”), seeking an indicative ruling on his request for relief from judgment under Rule 60(b)(6) based on the Ninth Circuit’s recent decision in United States ex rel. Silbersher v. Valeant Pharms. Int’l, Inc., 89 F.4th 1154 (9th Cir. Jan. 5, 2024) (“Valeant”). For the reasons stated below, the Court finds that relief under Rule 60(b)(6) is not warranted and therefore the Motion is DENIED. 1 A. Procedural Background In Relator’s First Amended Complaint (“FAC”), Relator asserted claims under the federal False Claims Act (“FCA”) and the false claims acts of various States based on allegations that Adamas and Allergan misled the United States Patent Office (“Patent Office”) into issuing invalid patents protecting the drugs Namenda XR® and Namzaric®, thus perpetuating their monopoly power and allowing them to overcharge the federal government and the States for these drugs under various programs, including Medicare and Medicaid. FAC ¶¶ 1-8. Adamas and Allergan brought motions to dismiss the FAC, challenging Relator’s claims on three grounds. First, they argued that the FCA claims were barred under the public disclosure bar that is found in 31 U.S.C. § 3730(e)(4) because all of the transactions on which Relator’s FCA fraud claims were based had been publicly disclosed in documents that were filed on the Patent Office’s Patent Application Information Retrieval (“PAIR”) website. Second, they argued that Relator does not fall under the “original source” exception to the public disclosure bar. Finally, they argued that Relator failed to allege facts sufficient to state any valid FCA claims against them under Rule 12(b)(6) of the Federal Rules of Civil Procedure. The Court denied the motions, finding that the FCA claims were adequately alleged under Rule 12(b)(6) and the public disclosure bar did not apply. Dkt. no. 135. As to the latter holding, the Court concluded that Relator’s claims were based on “substantially the same allegations or transactions” as the disclosures in the patent prosecution history, 31 U.S.C. § 3730(e)(4)(A), because all the material elements of the allegedly fraudulent transaction were disclosed in the patent prosecution history (as Relator conceded). Nonetheless, the Court found that the public disclosure bar did not apply because the disclosures were not made through one of the channels that triggers the public disclosure bar under the FCA. Id. The Court did not reach the question of whether Relator was an “original source.” Defendants asked the Court to certify its order for immediate appeal and the Court granted that request, observing that its order “addressed difficult questions of first impression with respect to the significance of recent amendments to the FCA” and noting that another judge of this Court reached a different conclusion as to whether disclosures in patent prosecution history trigger the public disclosure bar. Dkt. no. 147 at 4 (citing United States ex rel. Silbersher v. Valeant Pharmaceuticals International, Inc., No. 18-cv-1496 JD, N.D. Cal.). The Ninth Circuit accepted the interlocutory appeal and reversed this Court on the question of whether disclosures in the patent prosecution history fall within the ambit of the public disclosure bar, finding that they do. It declined to address Relator’s argument that this Court erred in finding that the “substantially the same allegations or transactions” requirement was met, concluding Relator had waived his arguments on that question before this Court. United States v. Allergan, Inc., 46 F.4th 991 (9th Cir. 2022). The court of appeals then remanded for this Court to consider whether Relator was an “original source” under 31 U.S.C. § 3730(e)(4)(A). On remand, Adamas and Allergan again brought motions to dismiss, asserting that Relator was not an “original source” because specialized expertise or background knowledge that helps a relator piece together a fraud claim from patent prosecution history is not sufficient to make a relator an original source. This Court agreed and therefore held that Relator was not an “original source” such that he could avoid the public disclosure bar. Dkt. no. 197. In the same order, the Court rejected Relator’s argument that the disclosures in the patent prosecution history did not involve “substantially the same allegations or transactions” as alleged in the FAC, citing its previous finding that “the prosecution histories of the patents at issue in this case disclose the material elements of the fraud that is the basis for Relator’s claim, both with respect to the Went Patents and the ’009 patent, as they reveal both the true and false state of affairs with respect to the alleged fraud.” Id. at 15 (citing dkt. no. 135 at 32). The Court further found that “[w]hile Relator has pointed to various categories of information he contends were not contained in the prosecution histories . . . all of them amount to conclusions he drew from analyzing the prosecution history using his specialized expertise in patent law; they do not change the Court’s conclusion that the also observed that “Relator conceded at the hearing on the previous motion to dismiss that the patent files contain ‘the relevant information from which the inference of fraud could be drawn.’” Id. (citing dkt. no. 116 at 9). On March 20, 2023, having found that the public disclosure bar applied to Relator’s FCA claims, the Court dismissed those claims with prejudice, declined to exercise supplemental jurisdiction over the state law claims, which were dismissed without prejudice, and entered judgment in favor of Allergan and Adamas. Dkt. nos. 197, 198. Relator appealed to the Ninth Circuit and that appeal is pending. B. Valeant After the Court entered judgment in favor of Allergan and Adamas, the Ninth Circuit issued its decision in Valeant. The original panel deci

Free access — add to your briefcase to read the full text and ask questions with AI

Silbersher v. Allergan plc, (N.D. Cal. 2024).

Silbersher v. Allergan plc (Silbersher v. Allergan plc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Jose B. Bueno
21 F.3d 120 (Sixth Circuit, 1994)
Robert Franklin v. District of Columbia
163 F.3d 625 (D.C. Circuit, 1999)
Phelps v. Alameida
569 F.3d 1120 (Ninth Circuit, 2009)
Amarin Pharmaceuticals Ireland Limited v. Food and Drug Administration
139 F. Supp. 3d 437 (District of Columbia, 2015)
Zachary Silbersher v. Allergan, Inc.
46 F.4th 991 (Ninth Circuit, 2022)
Medgraph, Inc. v. Medtronic, Inc.
310 F.R.D. 208 (W.D. New York, 2015)
Zachary Silbersher v. Valeant Pharmaceuticals Int'l
89 F.4th 1154 (Ninth Circuit, 2023)